
    
      A prospective study to evaluate the safety and efficacy of Chimeric antigen receptor T cells
      combined with Eps8 or WT1（Wilms tumor 1） peptide specific dendritic cell for patients with
      relapsed/refractory leukemia. There are options for CAR-targets: CD19, CD20, CD22 and CD10
      for acute lymphoblastic leukemia; CD33, CD38 CD56, CD117, CD123, CD34 and Muc1 for acute
      myeloid leukemia and Myelodysplastic Syndrome. Progression free survival, overall Survival,
      overall response rate, and duration of response were monitored.
    
  